Research brief · 2026-09-09
What 'Off-Label' Means
'Off-label' sounds like a warning, and sometimes it is. But the phrase describes a regulatory category, not a judgment about whether a use is wise.
When the FDA approves a drug, the approval is tied to a label. The label names the condition the drug was studied for, the population, the dose and the route. Off-label means a physician prescribes that approved drug for something the label does not cover: a different condition, a different age group, a different dose or form. The FDA's page on unapproved uses of approved drugs explains that this is legal, that the agency regulates drug approval and marketing rather than the practice of medicine, and that physicians may prescribe off-label when they judge it medically appropriate for a patient.
It is also common. A 2006 study in Archives of Internal Medicine by Radley, Finkelstein and Stafford examined prescribing patterns for 160 commonly used drugs and found that about 21 percent of prescriptions were off-label. Of those, 73 percent had little or no scientific support for the use in question.
That distinction turns out to matter. A 2016 study in JAMA Internal Medicine by Eguale and colleagues followed more than 46,000 patients and their prescriptions. Off-label uses backed by strong scientific evidence carried the same rate of adverse drug events as on-label uses. Off-label uses lacking strong evidence carried a 54 percent higher rate. The GLP-1 medications are a live example: semaglutide is approved for type 2 diabetes and chronic weight management, and any prescribing outside those labels is off-label by definition, with evidence that varies use by use.
The limit is that 'off-label' tells you about paperwork, not evidence. The right questions are whether human trials exist for that specific use and what they found. Those are questions for a physician who can read the evidence against a particular person's situation.
Sources
- U.S. Food and Drug Administration, Understanding Unapproved Use of Approved Drugs 'Off Label'
- FDA.gov 2018
- Radley DC, Finkelstein SN, Stafford RS, Off-label prescribing among office-based physicians
- Archives of Internal Medicine 2006
- Eguale T et al., Association of Off-label Drug Use and Adverse Drug Events in an Adult Population
- JAMA Internal Medicine 2016
Peptide Proof reports what studies found. We do not give medical advice, dosing guidance, or treatment recommendations.